Médecine

Paramédical

Autres domaines


S'abonner

Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis - 05/12/20

Doi : 10.1016/j.jaad.2020.08.032 
Richard G. Langley, MD a, Yves Poulin, MD b, Bhaskar Srivastava, MD, PhD c, Kimberly Parnell Lafferty, PharmD, MBA d, Steven Fakharzadeh, MD, PhD e, Wayne Langholff, PhD f, Matthias Augustin, MD, PhD g,
a Dalhousie University, Halifax, Canada 
b Université Laval, hôpital Hotel-Dieu de Québec and Centre de Recherche Dermatologique du Québec métropolitain, Quebec, Canada 
c Janssen Research & Development, LLC, Spring House, Pennsylvania 
d Janssen Scientific Affairs, LLC, Horsham, Pennsylvania 
e Janssen Global Services, LLC, Horsham, Pennsylvania 
f Janssen Research & Development, LLC, Horsham, Pennsylvania 
g University Medical Center, Hamburg-Eppendorf, Hamburg, Germany 

Correspondence to: Matthias Augustin, MD, PhD, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Martinistr 52, 20246 Hamburg, Germany.Institute for Health Services Research in Dermatology and NursingUniversity Medical Center HamburgMartinistr 52Hamburg20246Germany

Abstract

Background

The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.

Objective

To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry.

Methods

Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in the Psoriasis Longitudinal Assessment and Registry. Cases were matched (1:4) with controls by age, race, sex, and geographic region. Evaluated treatments included methotrexate, ustekinumab, and tumor necrosis factor α inhibitors. Exposure was defined as at least 1 dose of treatment within 3 months before death and was stratified by duration of therapy.

Results

Among 12,090 patients, 341 deaths occurred, matched to 1364 controls. Biologic treatment within the preceding 3 months was protective against mortality versus no exposure: odds ratio (OR) for exposure of less than 1 year, 0.08 (95% confidence interval [CI], 0.03-0.23); OR for exposure of 1 year or longer, 0.09 (95% CI, 0.06-0.13). Methotrexate was protective against mortality only with exposure for 1 year or longer (OR, 0.08; 95% CI, 0.02-0.28).

Limitations

Observational studies are subject to unmeasured confounding.

Conclusions

Biologic therapy was associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration; methotrexate reduced risk only with exposure for 1 year or longer.

Le texte complet de cet article est disponible en PDF.

Key words : biologic, methotrexate, mortality, PSOLAR, psoriasis, systemic, tumor necrosis factor, ustekinumab

Abbreviations used : BMI, BSA, CAD, CI, COPD, HR, OR, PAD, PGA, PSOLAR, PUVA, TNFi


Plan


 Funding sources: Supported by Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
 Disclosure: Dr Langley has served and has received compensation in the form of grant funding and/or honoraria as principal investigator for and is on the scientific advisory board or has served as a speaker for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB. Dr Poulin has received grant funding and honoraria for services as an investigator, speaker, and member of advisory boards from AbbVie, Amgen, Bausch, Centocor/Janssen-Ortho, and UCB and has received grant funding as an investigator from Baxter, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galderma, Genentech, GlaxoSmithKline, Eli Lilly, Incyte, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Serono, and Takeda. Dr Srivastava is employed by Janssen Research & Development, LLC and owns stock in Johnson & Johnson, of which Janssen is a subsidiary. Dr Lafferty is employed by Janssen Scientific Affairs, LLC, and owns stock in Johnson & Johnson, of which Janssen is a subsidiary. Dr Fakharzadeh is employed by Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen is a subsidiary. Dr Langholff is employed by Janssen Research & Development, LLC, and owns stock in Johnson & Johnson, of which Janssen is a subsidiary. Dr Augustin has served as a consultant to or paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Fresenius, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort.
 IRB approval status: Reviewed and approved by Goodwyn IRB, Cincinnati, OH, USA (C0168Z03).
 Reprints not available from the authors.


© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 1

P. 60-69 - janvier 2021 Retour au numéro
Article précédent Article précédent
  • Skin biopsy and skin cancer treatment use in the Medicare population, 1993 to 2016
  • Robert Skaggs, Brett Coldiron
| Article suivant Article suivant
  • Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study
  • Ahmed Yousaf, Swapna Gayam, Steve Feldman, Zachary Zinn, Michael Kolodney

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.